Drug Delivery Technology
The BeloGal® technology was developed by Double Bond Pharmaceutical and patent filings are in process (PCT/EP2017/025035). Freedom to Operate search in the US and EU determined no comparable drug delivery technologies. BeloGal is based on a biomimetic encapsulation of the API with polymer- and biologicals-free excipient, providing a radical increase of the therapeutic effect of the API at the target site, while protecting the remaining healthy tissues from toxic effects. Preliminary evidence shows 10x dose in lungs or liver vs. other organs. The technology is currently in development for lung and liver cancer therapies as well as for pneumonia treatment.